Literature DB >> 16185193

Targeting the chemokine receptor CXCR3 and its ligand CXCL10 in the central nervous system: potential therapy for inflammatory demyelinating disease?

Torben Lykke Sorensen1.   

Abstract

Multiple sclerosis is an inflammatory disease of the CNS and a leading cause of disability. Inflammatory mediators play an orchestrating part in lesional development leading to symptoms. Chemokines -- chemoattractant cytokines -- regulate the inflammatory composite of the MS lesion. This review focuses on the present data regarding CXCL10 (previously known as IP-10) and CXRC3 in multiple sclerosis, since consistent data has suggested that this chemokine/chemokine receptor pair has a pivotal role in leukocyte recruitment into the central nervous system (CNS) in multiple sclerosis.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 16185193     DOI： 10.2174/1567202043480143

Source DB:  PubMed          Journal:  Curr Neurovasc Res        ISSN： 1567-2026            Impact factor:   1.990


  9 in total

1.  Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes.

Authors:  Hongwei Qin; Sandrine A Niyongere; Sun Jung Lee; Brandi J Baker; Etty N Benveniste
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

2.  Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3.

Authors:  Karen M Lammers; Ruliang Lu; Julie Brownley; Bao Lu; Craig Gerard; Karen Thomas; Prasad Rallabhandi; Terez Shea-Donohue; Amir Tamiz; Sefik Alkan; Sarah Netzel-Arnett; Toni Antalis; Stefanie N Vogel; Alessio Fasano
Journal:  Gastroenterology       Date:  2008-03-21       Impact factor: 22.682

3.  CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin.

Authors:  Akihiko Ichikawa; Keiji Kuba; Masayuki Morita; Shinsuke Chida; Hiroyuki Tezuka; Hiromitsu Hara; Takehiko Sasaki; Toshiaki Ohteki; V Marco Ranieri; Claudia C dos Santos; Yoshihiro Kawaoka; Shizuo Akira; Andrew D Luster; Bao Lu; Josef M Penninger; Stefan Uhlig; Arthur S Slutsky; Yumiko Imai
Journal:  Am J Respir Crit Care Med       Date:  2012-11-09       Impact factor: 21.405

4.  Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers.

Authors:  Charlotte Liisborg; Vibe Skov; Lasse Kjær; Hans Carl Hasselbalch; Torben Lykke Sørensen
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

5.  The opioid antagonist, beta-funaltrexamine, inhibits chemokine expression in human astroglial cells.

Authors:  Randall L Davis; Daniel J Buck; Neda Saffarian; Craig W Stevens
Journal:  J Neuroimmunol       Date:  2007-05-01       Impact factor: 3.478

6.  Β-funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes.

Authors:  Randall L Davis; Subhas Das; Daniel J Buck; Craig W Stevens
Journal:  Neurochem Int       Date:  2013-01-31       Impact factor: 3.921

7.  Adult human glia, pericytes and meningeal fibroblasts respond similarly to IFNy but not to TGFβ1 or M-CSF.

Authors:  Amy M Smith; E Scott Graham; Sheryl Xia Feng; Robyn L Oldfield; Peter M Bergin; Edward W Mee; Richard L M Faull; Maurice A Curtis; Mike Dragunow
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

8.  Structure of mouse IP-10, a chemokine.

Authors:  Talat Jabeen; Philip Leonard; Haryati Jamaluddin; K Ravi Acharya
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2008-05-14

9.  Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Authors:  Hideaki Tahara; Marimo Sato; Magdalena Thurin; Ena Wang; Lisa H Butterfield; Mary L Disis; Bernard A Fox; Peter P Lee; Samir N Khleif; Jon M Wigginton; Stefan Ambs; Yasunori Akutsu; Damien Chaussabel; Yuichiro Doki; Oleg Eremin; Wolf Hervé Fridman; Yoshihiko Hirohashi; Kohzoh Imai; James Jacobson; Masahisa Jinushi; Akira Kanamoto; Mohammed Kashani-Sabet; Kazunori Kato; Yutaka Kawakami; John M Kirkwood; Thomas O Kleen; Paul V Lehmann; Lance Liotta; Michael T Lotze; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Hisahiro Matsubara; Shawmarie Mayrand-Chung; Kiminori Nakamura; Hiroyoshi Nishikawa; A Karolina Palucka; Emanuel F Petricoin; Zoltan Pos; Antoni Ribas; Licia Rivoltini; Noriyuki Sato; Hiroshi Shiku; Craig L Slingluff; Howard Streicher; David F Stroncek; Hiroya Takeuchi; Minoru Toyota; Hisashi Wada; Xifeng Wu; Julia Wulfkuhle; Tomonori Yaguchi; Benjamin Zeskind; Yingdong Zhao; Mai-Britt Zocca; Francesco M Marincola
Journal:  J Transl Med       Date:  2009-06-17       Impact factor: 5.531
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.